This site is intended for health professionals only

At the heart of general practice since 1960

Current clinical practice

The quality of both anticoagulation treatment and services are important parts of care for patients with AF. Sub-standards in either of these areas may lead to consequences including adverse events, non-adherence, long waiting times and poor patient experience.

Research has shown that almost 38,000 warfarin patients are receiving suboptimal anticoagulation in England alone, and that approximately 62% of NHS Trusts have no written clinical protocols in place for reassessing anticoagulation in AF patients with poor anticoagulation control.1

To estimate how many VKA- or NOAC-treated AF patients may be without adequate anticoagulation in your area or nationally, visit AF Budget Impact Model the tool to calculate the ‘Perfection Gap’.2

Disclaimer: This is a third party website owned and operated by Imperial College Health Partners.



Striving to 'Perfect'

The Perfect domain of Detect, Protect, Perfect aims to promote quality anticoagulation treatment and services to ensure all patients experience best practice care and have optimal protection from AF-related stroke. Opportunities for improvement that may be implemented in primary care practice include:3

  • Supporting patients in the correct use of their anticoagulation treatment, enabling them to self-manage and self-monitor
  • Providing patient education
  • Promoting adherence to anticoagulation therapy
  • Having clear protocols to optimise the quality of anticoagulation control
  • Using key performance indicators such as referral times, time in therapeutic range (TTR), adverse events
  • Regular service reviews

Click here to view ELIQUIS prescribing and adverse event reporting information.

Abbreviations

AF = Atrial Fibrillation NOAC = Non-VKA Oral Anticoagulant TTR = Time in Therapeutic Range VKA = Vitamin K Antagonist

References
  1. Anticoagulation UK. Out of range: audit of anticoagulation management in secondary care in England. May 2018. Accessed May 2019. Available at: http://www.anticoagulationuk.org/news/2018-05-14-anticoagulation-uk-is-pleased-to-publish-a-new-report-out-of-range-audit-of-anticoagulation-management-in-secondary-care-in-england.
  2. Imperial College Health Partners. AF Budget Impact Model. Accessed May 2019. Available at: https://imperialcollegehealthpartners.com/af-budget-impact-model/.
  3. London Clinical Networks. AF Toolkit: Detect, Protect, Perfect. Accessed May 2019. Available at: www.londonscn.nhs.uk/wp-content/uploads/2017/06/detect-protect-perfect-london-af-toolkit-062017.pdf.

YOU ARE ABOUT TO LEAVE THIS WEBSITE.

×

This link takes you to a third party website (outside of the Bristol-Myers Squibb Group and Pfizer Group). Bristol-Myers Squibb and Pfizer has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the applicable laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites.

If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site

YOU ARE ABOUT TO LEAVE THIS WEBSITE.

×

This link takes you to a third party website (outside of the Bristol-Myers Squibb Group and Pfizer Group). Bristol-Myers Squibb and Pfizer has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the applicable laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites.

If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site

YOU ARE ABOUT TO LEAVE THIS WEBSITE.

×

This link takes you to a third party website (outside of the Bristol-Myers Squibb Group and Pfizer Group). Bristol-Myers Squibb and Pfizer has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the applicable laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites.

If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site

Job code: 432UK1900440-01
Date of Prep: May 2019

Pfizer BMS logo